



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

January 21st, 2015

Corporate Relationship Department
The Bombay Stock Exchange Limited
Dalal Street., Fort
Mumbai 400 001

The Manager - Listing
M/s National Stock Exchange of India Ltd
"Exchange Plaza", Bandra – Kurla Complex
Bandra (E) Mumbai 400 051

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir,

Please find enclose herewith the Press Release for your information.

Thanking you

Yours faithfully,
For NATCO Pharma Limited


M Adinarayana
Company Secretary &
Vice President (Legal & Corp Affairs)



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

REF: PR/16/2015

Press Release

Hyderabad 21st January, 2015

Natco Pharma Ltd. today announced that the U.S. Supreme Court has remanded the case relating to Teva's U.S. Patent No. 5,800,808 ("US'808 patent") back to the United States Court of Appeals for the Federal Circuit for that court to review the patent's validity in accordance with a partially modified standard of review. The US'808 patent expires on Sept. 1, 2015. The Supreme Court made no finding as to the validity of the US'808 patent, but instead sent the case back to the Federal Circuit to consider the matter in view of the modified standard.

Forwarded for favour of publication

For NATCO Pharma Limited

M. Adinarayana
Company Secretary &
Vice President (Legal & Corp Affairs)